Evidence map›Paper›PMID 37342373›Full record

ReviewAdvanced pharmaceutical bulletin2023

Current and Novel Emerging Medical Therapies for Peripheral Artery Disease: A Literature Review.

AmirAhmad Arabzadeh, Elnaz Faghfuri, Saiedeh Razi Soofiyani, Elaheh Dalir Abdolahinia, Samaneh Siapush, Kazem Nejati-Koshki, Bita Shahrami, Vahid Asghariazar, Yasamin Pahlavan

Open access · diamondAbstract readReview
In one paragraph

Review in Advanced pharmaceutical bulletin, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

AmirAhmad ArabzadehDepartment of Surgery, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran.ORCID https://orcid.org/0000-0001-9594-5522
Elnaz FaghfuriDigestive Disease Research Center, Ardabil University of Medical Sciences, Ardabil, Iran.
Saiedeh Razi SoofiyaniDepartment of Molecular Medicine, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Elaheh Dalir AbdolahiniaResearch Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
Samaneh SiapushDepartment of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Kazem Nejati-KoshkiPharmaceutical Sciences Research Center, Ardabil University of Medical Sciences, Ardabil, Iran.
Bita ShahramiDepartment of Clinical Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Vahid AsghariazarImmunology Research Center, Ardabil University of Medical Sciences, Ardabil, Iran.
Yasamin PahlavanBiosensor Sciences and Technologies Research Center, Ardabil University of Medical Sciences, Ardabil, Iran.ORCID https://orcid.org/0000-0002-4681-8807
Ardabil University of Medical Sciences · IRTabriz University of Medical Sciences · IRTehran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the improvements in endovascular techniques during the last decades, there is still an increase in the prevalence of peripheral artery disease (PAD) with limited practical treatment, which timeline impact of any intervention for critical limb ischemia (CLI) is poor. Most common treatments are not suitable for many patients due to their underlying diseases, including aging and diabetes. On the one hand, there are limitations for current therapies due to the contraindications of some individuals, and on the other hand, there are many side effects caused by common medications, for instance, anticoagulants. Therefore, novel treatment strategies like regenerative medicine, cell-based therapies, Nano-therapy, gene therapy, and targeted therapy, besides other traditional drugs combination therapy for PAD, are newly considered promising therapy. Genetic material encoding for specific proteins concludes with a potential future for developed treatments. Novel approaches for therapeutic angiogenesis directly used the angiogenetic factors originating from key biomolecules such as genes, proteins, or cell-based therapy to induce blood vessel formation in adult tissues to initiate the recovery process in the ischemic limb. As PAD is associated with high mortality and morbidity of patients causing disability, considering the limited treatment choices for these patients, developing new treatment strategies to prevent PAD progression and extending life expectancy, and preventing threatening complications is urgently needed. This review aims to introduce the current and the novel strategies for PAD treatment that lead to new challenges for relief the patient's suffered from the disorder.

Indexed as

AngiogenesisCell therapyGene therapyNano-therapyPeripheral artery disease (PAD)

Identifiers

PMID37342373
PMCPMC10278215
OpenAlexW4292234711

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.